Reflux Esophagitis Phase III Study (Maintenance Treatment)

PHASE3CompletedINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

January 31, 2008

Study Completion Date

May 31, 2009

Conditions
Reflux Esophagitis
Interventions
DRUG

Esomeprazole

10mg once daily oral administration

DRUG

Esomeprazole

20mg once daily oral administration

DRUG

Omeprazole

10mg once daily oral administration

Trial Locations (44)

Unknown

Research Site, Akita

Research Site, Kashiwa

Research Site, Kisarazu

Research Site, Kōriyama

Research Site, Nihonmatsu

Research Site, Nishishirakawa

Research Site, Fukuoika

Research Site, Fukuoka

Research Site, Kurume

Research Site, Nukaya

Research Site, Fukuoka

Research Site, Kōriyama

Research Site, Shirakawa

Research Site, Sugawa

Research Site, Gifu

Research Site, Maebashi

Research Site, Yasunaka

Research Site, Sapporo

Research Site, Hitachi

Research Site, Mito

Research Site, Tsukuba

Research Site, Sakaidechō

Research Site, Takamatsu

Research Site, Fujisawa

Research Site, Kawasaki

Research Site, Sagamihara

Research Site, Yokohama

Research Site, Kyoto

Research Site, Shibata

Research Site, Kiso

Research Site, Matsumoto

Research Site, Ōita

Research Site, Fujiidera

Research Site, Toyonaka

Research Site, Shizuoka

Research Site, Ohtawara

Research Site, Toshima-ku

Research Site, Adachi City

Research Site, Hachiōji

Research Site, Kiyose

Research Site, Setagaya City

Research Site, Shinagawa

Research Site, Tottori-shi

Research Site, Shimonoseki

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY